Table 3.
Variable | Hazard ratio | 95% confidence interval | P‐value |
---|---|---|---|
Age (≥65) | 1.78 | 0.570–5.559 | 0.3212 |
Sex (male) | 3.26 | 0.732–14.489 | 0.1210 |
Performance status (≥1) | 2.36 | 0.687–8.078 | 0.1728 |
Metastasis (≥3) | 1.58 | 0.450–5.561 | 0.4739 |
Chemotherapy (5‐FU) | 1.48 | 0.402–5.475 | 0.5541 |
DACH1 | 0.38 | 0.175–0.817 | 0.0134 |
EGFR | 1.41 | 0.992–2.001 | 0.0553 |
MT1X | 0.71 | 0.317–1.600 | 0.4111 |
YWHAE | 1.91 | 0.401–9.061 | 0.4169 |
GPX3 | 1.62 | 0.869–3.007 | 0.1293 |
PDCD6 | 0.06 | 0.010–0.334 | 0.0015 |
WDR33 | 1.38 | 0.268–7.067 | 0.7017 |
C14orf43 | 0.64 | 0.122–3.407 | 0.6045 |
MYLIP | 0.67 | 0.221–2.042 | 0.4826 |
GKAP1 | 2.31 | 0.751–7.106 | 0.1440 |
Cox regression model was performed for multivariate analysis against each of the variables.